X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs VENUS REMEDIES - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD VENUS REMEDIES ORCHID PHARMA LTD/
VENUS REMEDIES
 
P/E (TTM) x -0.2 -1.4 - View Chart
P/BV x 0.1 0.1 114.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   VENUS REMEDIES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
VENUS REMEDIES
Mar-18
ORCHID PHARMA LTD/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs194126 154.1%   
Low Rs3561 57.3%   
Sales per share (Unadj.) Rs276.5301.8 91.6%  
Earnings per share (Unadj.) Rs-79.2-24.9 318.5%  
Cash flow per share (Unadj.) Rs-43.52.5 -1,707.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.9293.3 18.4%  
Shares outstanding (eoy) m70.4512.34 570.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.40.3 133.7%   
Avg P/E ratio x-1.4-3.8 38.5%  
P/CF ratio (eoy) x-2.636.7 -7.2%  
Price / Book Value ratio x2.10.3 665.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,0671,154 699.1%   
No. of employees `0002.80.9 302.7%   
Total wages/salary Rs m2,527393 642.8%   
Avg. sales/employee Rs Th6,956.14,026.1 172.8%   
Avg. wages/employee Rs Th902.5425.0 212.4%   
Avg. net profit/employee Rs Th-1,993.0-331.8 600.7%   
INCOME DATA
Net Sales Rs m19,4773,724 523.0%  
Other income Rs m40723 1,809.8%   
Total revenues Rs m19,8843,747 530.7%   
Gross profit Rs m1,103395 279.3%  
Depreciation Rs m2,519338 744.7%   
Interest Rs m5,227354 1,475.2%   
Profit before tax Rs m-6,236-275 2,265.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-12532 -396.2%   
Profit after tax Rs m-5,580-307 1,818.3%  
Gross profit margin %5.710.6 53.4%  
Effective tax rate %2.0-11.5 -17.5%   
Net profit margin %-28.7-8.2 347.7%  
BALANCE SHEET DATA
Current assets Rs m11,0142,638 417.6%   
Current liabilities Rs m32,0602,305 1,391.1%   
Net working cap to sales %-108.18.9 -1,208.3%  
Current ratio x0.31.1 30.0%  
Inventory Days Days95135 70.1%  
Debtors Days Days3446 72.4%  
Net fixed assets Rs m29,4404,871 604.4%   
Share capital Rs m705123 570.9%   
"Free" reserves Rs m2,0433,496 58.4%   
Net worth Rs m3,8003,619 105.0%   
Long term debt Rs m9,0181,374 656.1%   
Total assets Rs m46,5107,509 619.4%  
Interest coverage x-0.20.2 -86.6%   
Debt to equity ratio x2.40.4 624.9%  
Sales to assets ratio x0.40.5 84.4%   
Return on assets %-0.80.6 -120.4%  
Return on equity %-146.9-8.5 1,731.8%  
Return on capital %-3.71.6 -236.1%  
Exports to sales %37.90-   
Imports to sales %22.613.9 163.1%   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406517 853.0%   
Fx inflow Rs m7,5130-   
Fx outflow Rs m5,649517 1,093.7%   
Net fx Rs m1,865-517 -361.0%   
CASH FLOW
From Operations Rs m1,682514 326.9%  
From Investments Rs m-9,860-123 8,010.1%  
From Financial Activity Rs m6,644-387 -1,716.3%  
Net Cashflow Rs m-1,5354 -36,547.6%  

Share Holding

Indian Promoters % 32.3 32.9 98.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 0.2 2,555.6%  
FIIs % 3.3 0.6 569.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 66.4 83.3%  
Shareholders   84,811 20,121 421.5%  
Pledged promoter(s) holding % 54.9 36.4 151.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  NATCO PHARMA  DIVIS LABORATORIES  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 490 Points Higher; Oil & Gas and Telecom Stocks Witness Buying(Closing)

Indian share markets continued to witness buying interest and ended their trading session on a positive note. Gains were largely seen in the oil & gas sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Apr 24, 2019 03:37 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS